-
公开(公告)号：KR1020110001915A
公开(公告)日：2011-01-06
申请号：KR1020100060309
申请日：2010-06-25
Applicant: (주)아모레퍼시픽
CPC classification number: A61K36/73 , A61K8/97 , A61Q19/08 , A61K2800/74 , A61K2800/805
Abstract: PURPOSE: A cosmetic composition containing Rubus coreanus extract is provided to suppress formation of SNARE complex and to improve anti-wrinkling. CONSTITUTION: A cosmetic composition for improving anti-wrinkling contains 0.0001-30 weight% of Rubus coreanus extract as an active ingredient. The Rubus coreanus extract is obtained from fruit of Rubus coreanus Miquel using 80% ethanol. The Rubus coreanus is pretreated by steaming at 120-150°C for 3-6 hours, roasting at 100-180°C for 10 minutes to one hour and 80-100°C for 10 minutes to one hour.
Abstract translation: 目的：提供含有Rubus coreanus提取物的化妆品组合物，以抑制SNARE复合物的形成并改善抗皱纹。 构成：用于改善抗皱纹的化妆品组合物含有0.0001-30重量％的木薯提取物作为活性成分。 使用80％乙醇从Rubus coreanus Miquel的果实获得Rubus coreanus提取物。 通过在120-150℃蒸煮3-6小时，在100-180℃下烘烤10分钟至1小时，80-100℃，10分钟至1小时进行预处理。
-
公开(公告)号：KR1020100026855A
公开(公告)日：2010-03-10
申请号：KR1020080086021
申请日：2008-09-01
Applicant: (주)아모레퍼시픽
CPC classification number: A61K36/82 , A61K36/21 , A61K36/232 , A61K36/234 , A61K36/48 , Y10S514/844 , Y10S514/857 , Y10S514/886
Abstract: PURPOSE: A skin external composition for preventing or treating inflammatory dermatitis containing natural products is provided to ensure anti-inflammation and skin moisturization. CONSTITUTION: A skin external composition for preventing or treating inflammatory dermatitis contains 0.001-20 weight% of green tea, 0.05-3 weight% of sophora root, 0.05-3 weight% of Portulaca oleracea L., and 0.5-30 weight% of Polygonatum officinale as active ingredient. The skin external composition additionally contains 1-50 weight% of starch, 1-10 weight% of cacao bean, 1-10 weight% of Cnidii Rhizoma or 0.5-5 weight% of Angelicae gigantis Radix. The composition is cosmetic composition or pharmaceutical composition.
Abstract translation: 目的：提供用于预防或治疗含有天然产物的炎性皮炎的皮肤外用组合物，以确保抗炎和皮肤保湿。 构成：用于预防或治疗炎症性皮炎的皮肤外用组合物含有绿茶的重量百分比为0.001-20重量％，槐根0.05-3重量％，马齿苋属0.05-3重量％，黄芪0.5-30重量％ 草药作为活性成分。 皮肤外用组合物另外含有1-50重量％的淀粉，1-10重量％的可可豆，1-10重量％的Cnidii Rhizoma或0.5-5重量％的Angelicae gigantis大戟。 组合物是化妆品组合物或药物组合物。
-
53.发明公开
公开(公告)号：KR1020080097420A
公开(公告)日：2008-11-05
申请号：KR1020087019182
申请日：2007-02-14
Applicant: (주)아모레퍼시픽
IPC: A61K31/17 , A61K31/765 , A61P17/00
CPC classification number: A61K9/0014 , A61K31/17 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/26 , A61K47/32
Abstract: A composition for external application for treating and preventing the pruritus or irritant skin disease is provided to have excellent fluxes and stability by containing the thiourea derivative and to be useful in pruritus or irritant skin disease. A composition for external application of O/w-shaped emulsion form comprises (1) drug expressed as a compound of a chemical formula 1, (2) a component selected from a group consisting of squalene, dimethicone, propylene glycol, butylene glycol and mineral oil, (3) a component selected from a group consisting of polyethylene glycol 400, polyoxyethylene alkyl ether, cetyl alcohol and solbitan stearate, (4) water and (5) a component selected from a group consisting of ethanol, twin 60, carbomer 940, EDTA.2Na and triethanolammine.
Abstract translation: 提供用于治疗和预防瘙痒或刺激性皮肤病的外用组合物，通过含有硫脲衍生物具有优异的通量和稳定性，并且可用于瘙痒或刺激性皮肤病。 用于外用O / W型乳液形式的组合物包括（1）以化学式1化合物表示的药物，（2）选自角鲨烯，聚二甲基硅氧烷，丙二醇，丁二醇和矿物质的组分 油，（3）选自聚乙二醇400，聚氧乙烯烷基醚，鲸蜡醇和硬脂酸solbitan的组分，（4）水和（5）选自乙醇，双螺杆菌60，卡波姆940 ，EDTA.2Na和三乙醇胺。
-
公开(公告)号：KR1020070085422A
公开(公告)日：2007-08-27
申请号：KR1020077011568
申请日：2005-11-30
Applicant: (주)아모레퍼시픽
IPC: C07C251/44 , C07C251/32
CPC classification number: C07C317/32 , C07C251/44 , C07C255/61 , C07C259/18 , C07C323/47 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07D209/08 , C07D213/53 , C07D307/91 , C07D317/58 , C07D333/22 , C07D333/58 , C07D339/08
Abstract: Provided are a 2-cyclopenten-1-one oxime derivative which inhibits the production of TNF-alpha or PEF4, its pharmaceutically acceptable salt, and a pharmaceutical composition containing the derivative for treating or preventing the TNF-alpha mediated disease. A 2-cyclopenten-1-one oxime derivative is represented by the formula(1), wherein R1 is a linear or branched C1-C10 alkyl group or a C3-C7 cycloalkyl group; and R2 is a substituted or unsubstituted aromatic group. Preferably the aromatic group of R2 is selected from a phenyl group, a pyridyl group, a naphthyl group, an indolyl group, a thienyl group, a benzo[b]thienyl group, a dibenzofuranyl group, or a thianthrenyl group.
Abstract translation: 提供抑制TNF-α或PEF4的生成的2-环戊烯-1-酮肟衍生物及其药学上可接受的盐，以及含有用于治疗或预防TNF-α介导的疾病的衍生物的药物组合物。 2-环戊烯-1-酮肟衍生物由式（1）表示，其中R 1是直链或支链C 1 -C 10烷基或C 3 -C 7环烷基; R2是取代或未取代的芳基。 优选R2的芳基选自苯基，吡啶基，萘基，吲哚基，噻吩基，苯并[b]噻吩基，二苯并呋喃基或噻蒽基。
-
公开(公告)号：KR1020050090356A
公开(公告)日：2005-09-13
申请号：KR1020050078835
申请日：2005-08-26
Applicant: (주)아모레퍼시픽
Inventor： 서영거 , 오우택 , 김희두 , 이지우 , 박형근 , 박옥희 , 이용실 , 박영호 , 주영협 , 최진규 , 임경민 , 김선영 , 김진관 , 고현주 , 모주현 , 정연수 , 이정범 , 오영임
IPC: A61K31/17
CPC classification number: C07D333/42 , C07C311/08 , C07C311/47 , C07C333/20 , C07C335/12 , C07C335/14 , C07C335/20 , C07C335/26 , C07C2601/14 , C07C2602/10 , C07D207/323 , C07D207/416 , C07D207/42 , C07D209/08 , C07D209/14 , C07D213/40 , C07D213/61 , C07D213/76 , C07D217/06 , C07D231/14 , C07D231/56 , C07D233/64 , C07D235/14 , C07D239/42 , C07D241/12 , C07D241/24 , C07D277/28 , C07D295/13 , C07D295/215 , C07D295/32 , C07D307/52 , C07D311/58 , C07D317/58 , C07D333/20
Abstract: 본 발명은 바닐로이드 수용체(Vanilloid Receptor; VR)에 대한 조절제로서 신규한 티오우레아 유도체를 함유하는 약제학적 조성물에 관한 것이다.
바닐로이드 수용체의 활성과 연관된 질환에는 통증, 급성 통증, 만성 통증, 신경병적 통증, 수술후 통증, 편두통, 관절통, 신경병증, 신경손상, 당뇨병성 신경병, 신경변성 질환, 신경성 피부질환, 뇌졸중, 방광과민증, 과민성 장증후군, 천식과 만성폐색성 폐질환등 호흡기 이상, 피부, 눈, 점막의 자극, 발열, 위-십이지장궤양, 염증성 장 질환 및 염증성 질환 등이 포함될 수 있다. 본 발명은 이들 질환의 예방, 치료를 위한 약제학적 조성물을 제공한다.-
Patent Agency Ranking
公开(公告)号：KR101736979B1
公开(公告)日：2017-05-19
申请号：KR1020100088082
申请日：2010-09-08
Applicant: (주)아모레퍼시픽
IPC: A61K36/73 , A61K36/736 , A61K8/97 , A61Q19/00
CPC classification number: A61K36/736 , A61K8/97 , A61K36/73 , A61Q19/00
Abstract: 본발명은오매(Prunus mume) 추출물을유효성분으로함유하는레이저시술후의애프터케어용피부외용제조성물을제공한다.본발명의피부외용제조성물은피부진정, 피부장벽회복및 통증완화효능을가지고있어서, 민감성피부보호, 피부민감성방지, 피부안정감제공및 보습효과를추가적으로가지는화장료조성물로개발될수 있다.
Abstract translation: 本发明提供一种含有梅的提取物作为有效成分的激光治疗后的护理用皮肤外用组合物本发明的皮肤外用组合物具有皮肤镇静，恢复皮肤屏障和缓解疼痛， 皮肤保护，皮肤敏感度，皮肤感觉和保湿效果。
-
公开(公告)号：KR1020170038364A
公开(公告)日：2017-04-07
申请号：KR1020150137650
申请日：2015-09-30
Applicant: (주)아모레퍼시픽
Abstract: 본발명은중공관형태의관통구를포함하는침관, 상기침관이고정되는구멍을포함하는침기및 상기침관을관통하여침관의선단부에서봉합사를끼우기위한고리를형성하고실 양쪽끝단이침관의후단부로빠져나온유도실을포함하는피부시술도구및 키트에관한것이다. 본발명은봉합사를유도실이형성하는고리에끼움으로써, 침관의두께에영향받지않고다양한굵기또는형태를갖는봉합사의사용이가능하며, 종래두꺼운굵기의침관으로인해발생했던부작용을감소시키고피부시술효과를증대시킬수 있다. 또한, 유도실양쪽끝단을침관후단부로빠져나오게하여유도실고정부또는유도실고정덮개로고정함으로써피부시술시실밀림을방지할수 있다.
Abstract translation: 本发明chimgwan，包括一个通孔在该处形成通过chimgwan以形成用于在chimgwan渗透的远端部和所述容纳孔chimgwan嵌合缝线被固定的环和室中的chimgwan的后端的两端部 皮肤处理工具和包括引出室的套件。 本发明允许使用具有通过将缝线环到感应室具有不同的厚度或类型的缝合线形成，而不受所述chimgwan的厚度，并减少这在常规的厚的厚度和皮肤的治疗chimgwan发生因副作用 效果可以增加。 此外，通过固定两端感应室chimgwan后端部分衍生斯莱戈政府或固定到盖引导室被压出，以防止皮肤处理西西里丛林。
-
58.发明授权바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물 有权其新型化合物异构体或其药学上可接受的盐作为VANILLOID受体拮抗剂和含有该抗体的药物组合物
公开(公告)号：KR101621444B1
公开(公告)日：2016-05-19
申请号：KR1020117002414
申请日：2009-07-02
Applicant: (주)아모레퍼시픽
Inventor： 우병영 , 김선영 , 김연준 , 신송석 , 김진관 , 이기화 , 김동현 , 임경민 , 모주현 , 정연수 , 최진규 , 고현주 , 이정오 , 김혁 , 윤정훈 , 리,푸난 , 김지숙 , 서영거
IPC: C07D263/36 , C07D277/22 , A61K31/421 , A61P25/00
CPC classification number: C07D263/42 , C07D263/34 , C07D263/38 , C07D263/48 , C07D277/42 , C07D277/56 , C07D307/52 , C07D307/68 , C07D333/38 , C07D413/04 , C07D413/12
Abstract: 본발명은바닐로이드수용체(Vanilloid Receptor 1; VR1; TRPV1) 길항제로작용하는신규화합물, 이의이성질체또는이의약제학적으로허용가능한염; 및이를포함하는약학조성물에관한것이다. 본발명은통증, 편두통(migraine), 관절통(arthralgia), 신경통(neuralgia), 신경장해(neuropathies), 신경손상(nerve injury), 피부질환(skin disorder), 비뇨방광과민증(urinary bladder hypersensitiveness), 과민성대장증후군(irritable bowel syndrome), 절박배변(fecal urgency), 호흡기질환(respiratory disorder), 피부, 눈또는점막자극(irritation of skin, eye or mucous membrane), 위-십이지장궤양(stomach-duodenal ulcer), 염증질병(inflammatory diseases), 귓병(ear disease), 심장병(heartdisease) 등과같은질병의예방또는치료용약학조성물을제공한다.
-
公开(公告)号：KR1020150001070A
公开(公告)日：2015-01-06
申请号：KR1020130073708
申请日：2013-06-26
Applicant: (주)아모레퍼시픽
IPC: A61K31/715 , A61K31/70 , A61K8/73 , A61P17/00
CPC classification number: A61K31/737 , A23L29/30 , A23V2200/318 , A61K8/73 , A61K9/0019 , A61K31/728
Abstract: 본 명세서는 글루코스아미노글라이칸의 하나인 콘드로이친설페이트와 히알루론산을 함유하는 콜라겐의 생성을 촉진하는 조성물에 관한 것으로서, 피부 조직에 처리하였을 때 뛰어난 콜라겐 생성 효과를 나타내고, 피부 조직을 수복시키는 것을 촉진 하는 조성물에 관한 것이다.
Abstract translation: 本说明书涉及促进产生胶原蛋白的组合物，包括作为一种糖胺聚糖的硫酸软骨素和透明质酸，并且涉及当组合物处理皮肤组织时对胶原产生具有优异效果的组合物 并促进皮肤组织的恢复。
-
公开(公告)号：KR1020130060684A
公开(公告)日：2013-06-10
申请号：KR1020110126881
申请日：2011-11-30
Applicant: (주)아모레퍼시픽
IPC: A61N1/18 , A61M5/178 , A61M5/158 , A61K31/575
Abstract: PURPOSE: A lipolysis kit is provided to alleviate pain, bruise, red spots, edema, pruritus, etc. which are caused by a lipolysis shot by having injection liquid containing a low frequency stimulator and a lipolysis material. CONSTITUTION: A lipolysis kit comprises a lipolysis material and a low frequency stimulator. A lipolysis means includes a composition for lipolysis, and a transfer mechanism to transfer the composition for lipolysis to a target area. The composition for lipolysis includes at least one or more of lipid, bile acid or salt thereof, a beta adrenalin receptor effector, and hyaluronidase. The composition for lipolysis contains at least one or more of deoxycholic acid, cholic acid, chenodeoxycholic acid, 7-alpha-dehydroxylate chenodeoxycholic acid, litho cholic acid, ursodeoxycholic acid, dihydroxy taurine acid, trihydroxy taurine acid or salt thereof, phosphatidylcholine, hyaluronidase, aminophylline, theophylline, isoproterenol, and salbutamol and salmeterol or salt thereof. The transfer mechanism includes at least one of a syringe containing one needle, a syringe containing multiple needles, a patch, and a micro needle. [Reference numerals] (AA) Δupper arm girth(cm); (BB) PPC + low frequency wave; (CC) 50% improvement; (DD) -after 2-3 days, measurement of upper arm girth
Abstract translation: 目的：提供脂解酶，以减轻由含有低频刺激剂和脂肪分解物质的注射液引起的脂解引起的疼痛，瘀伤，红点，水肿，瘙痒等。 构成：脂肪分解试剂盒包含脂肪分解物质和低频刺激剂。 脂肪分解方法包括用于脂肪分解的组合物和将脂肪分解组合物转移到目标区域的转移机理。 用于脂解的组合物包括至少一种或多种脂质，胆汁酸或其盐，β肾上腺素受体效应物和透明质酸酶。 用于脂解的组合物含有脱氧胆酸，胆酸，鹅脱氧胆酸，7-α-脱羟酸甲酯脱氧胆酸，石蜡酸，熊去氧胆酸，二羟基牛磺酸，三羟基牛磺酸或其盐，磷脂酰胆碱，透明质酸酶， 氨茶碱，茶碱，异丙肾上腺素和沙丁胺醇以及沙美特罗或其盐。 传送机构包括至少一个包含一个针的注射器，包含多个针的注射器，贴片和微针。 （附图标记）（AA）Δupper臂围（cm）; （BB）PPC +低频波; （CC）50％改善; （DD） - 2-3天后，测量上臂周长
-
-
-
-
-
-
-
-
-
Search Results
91
records
(took 0.033 seconds)
